Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 5/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425647 | 0.89 | GRIN2C (0.47) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4418806 | 0.85 | GRIN2C (0.49) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4416858 | 0.85 | GRIN2C (0.56) | GRIN2CMEN1KMT2A | |
| SCHEMBL4412003 | 0.84 | GRIN2C (0.55) | GRIN2CTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL4423031 | 0.83 | NPC1 (0.53) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4416759 | 0.82 | GRIN2C (0.53) | GRIN2CMEN1KMT2A | |
| SCHEMBL4418766 | 0.82 | MTNR1B (0.51) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4421922 | 0.79 | KMT2A (0.46) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4413414 | 0.77 | HTT (0.43) | GRIN2CMTNR1BALDH1A1MAPTHPGD | |
| SCHEMBL4417014 | 0.77 | MTNR1B (0.44) | GRIN2CMTNR1BALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | GRIN2C 567/4885TAS1R3 669/4885TAS1R1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.